https://www.korlym.com/hcp 2026-04-30 https://www.korlym.com/images/hcp/site-nav-korlym-logo.svg Korlym® (mifepristone) 300 mg tablets logo. https://www.korlym.com/images/hcp/_optimized/homepage-custom-type-opt-1080.WEBP Hypercortisolism. https://www.korlym.com/images/hcp/_optimized/24percent-graphic-opt-2048.WEBP Twenty-four percent. https://www.korlym.com/images/hcp/_optimized/24percent-graphic_mobile-opt-1080.WEBP Twenty-four percent. https://www.korlym.com/images/hcp/icons/reduction-hba1c.svg HbA1c. https://www.korlym.com/images/footer-corcept-logo-202x80.svg Corcept Logo https://www.korlym.com/hcp/site-map 2026-04-30 https://www.korlym.com/images/hcp/site-nav-korlym-logo.svg Korlym® (mifepristone) 300 mg tablets logo. https://www.korlym.com/images/footer-corcept-logo-202x80.svg Corcept Logo https://www.korlym.com/hcp/understanding-hypercortisolism 2026-04-30 https://www.korlym.com/images/hcp/site-nav-korlym-logo.svg Korlym® (mifepristone) 300 mg tablets logo. https://www.korlym.com/images/hcp/_optimized/24percent-graphic-opt-2048.WEBP Twenty-four percent. https://www.korlym.com/images/hcp/_optimized/24percent-graphic_mobile-opt-1080.WEBP Twenty-four percent. https://www.korlym.com/images/hcp/icons/3.5x.svg Approximately three and a half times. https://www.korlym.com/images/hcp/icons/2.0x.svg Approximately two times. https://www.korlym.com/images/footer-corcept-logo-202x80.svg Corcept Logo https://www.korlym.com/hcp/mechanism-of-action 2026-05-01 https://www.korlym.com/images/hcp/site-nav-korlym-logo.svg Korlym® (mifepristone) 300 mg tablets logo. https://www.korlym.com/images/hcp/moa/_optimized/moagrab-1-opt-1920.WEBP Glucocorticoid receptors in a cellular environment, with one receptor highlighted and labeled 'Glucocorticoid Receptor' against a gradient blue-gray background. https://www.korlym.com/images/hcp/moa/_optimized/moagrab-2-opt-1920.WEBP Cortisol molecule highlighted and labeled in a cellular environment against a gradient blue-gray background. https://www.korlym.com/images/hcp/moa/_optimized/moagrab-3-opt-1920.WEBP Molecular structure labeled 'KORLYM' bound to a GC receptor in a cellular environment against a gradient blue-gray background. https://www.korlym.com/images/footer-corcept-logo-202x80.svg Corcept Logo https://www.korlym.com/hcp/korlym-mechanism-of-action-video 2026-05-01 https://www.korlym.com/images/hcp/site-nav-korlym-logo.svg Korlym® (mifepristone) 300 mg tablets logo. https://www.korlym.com/images/footer-corcept-logo-202x80.svg Corcept Logo https://www.korlym.com/hcp/efficacy/seismic-study-results 2026-05-01 https://www.korlym.com/images/hcp/site-nav-korlym-logo.svg Korlym® (mifepristone) 300 mg tablets logo. https://www.korlym.com/images/hcp/icons/reduction-hba1c.svg HbA1c. https://www.korlym.com/images/hcp/charts/mean-change-in-oGTT_desktop.svg Graph showing significant improvements in oGTT as early as Week 6 and through Week 24 in the SEISMIC study. https://www.korlym.com/images/hcp/charts/auc-by-visit_desktop.svg Graph showing significant improvements in AUCinsulin at week 6 and week 24/ET with changes at weeks 6, 10, and 16 in the SEISMIC study. https://www.korlym.com/images/hcp/charts/mean-change-in-hba1c_desktop.svg Graph showing patients achieving a 1.1% mean reduction in HbA1c by Week 24 in the SEISMIC study. https://www.korlym.com/images/hcp/icons/47percent.svg Forty-seven percent. https://www.korlym.com/images/hcp/icons/42percent.svg Forty-two percent. https://www.korlym.com/images/hcp/charts/change-in-body-weight_desktop.svg Graph showing Korlym patients achieving 5.7% reduction in weight at Week 24/ET in the SEISMIC study. https://www.korlym.com/images/hcp/icons/50percentWhite.svg More than fifty percent. https://www.korlym.com/images/hcp/icons/25percentWhite.svg More than twenty-five percent. https://www.korlym.com/images/hcp/charts/change-in-median-BDI-II_desktop.svg Graph showing Korlym patients achieving improvements in depression at Week 24/ET in the SEISMIC study. https://www.korlym.com/images/footer-corcept-logo-202x80.svg Corcept Logo https://www.korlym.com/images/hcp/charts/weeks-of-treatment_desktop.svg Korlym dose by weeks of treatment. https://www.korlym.com/hcp/efficacy/catalyst-study-results 2026-05-01 https://www.korlym.com/images/hcp/site-nav-korlym-logo.svg Korlym® (mifepristone) 300 mg tablets logo. https://www.korlym.com/images/hcp/icons/reduction-hba1c.svg HbA1c. https://www.korlym.com/images/hcp/charts/significant-hba1c-reductions-desktop.svg Graph showing patients achieving a significant 1.32% mean reduction in HbA1c by Week 24 in the CATALYST study. https://www.korlym.com/images/hcp/charts/catalyst-change-in-baseline_desktop.svg Bar graph showing LS Mean change in HbA1c (%) from baseline for patients with and without adrenal abnormalities. https://www.korlym.com/images/footer-corcept-logo-202x80.svg Corcept Logo https://www.korlym.com/hcp/safety 2026-04-30 https://www.korlym.com/images/hcp/site-nav-korlym-logo.svg Korlym® (mifepristone) 300 mg tablets logo. https://www.korlym.com/images/footer-corcept-logo-202x80.svg Corcept Logo https://www.korlym.com/hcp/dosing/before-starting-korlym 2026-04-30 https://www.korlym.com/images/hcp/site-nav-korlym-logo.svg Korlym® (mifepristone) 300 mg tablets logo. https://www.korlym.com/images/hcp/icons/starting-step-1.svg Step One: Rule Out. https://www.korlym.com/images/hcp/icons/starting-step-2.svg Step Two: Check. https://www.korlym.com/images/hcp/icons/starting-step-3.svg Step Three: Evaluate. https://www.korlym.com/images/hcp/icons/starting-step-4.svg Step Four: Inform. https://www.korlym.com/images/hcp/icons/starting-step-5.svg Step Five: Discuss. https://www.korlym.com/images/footer-corcept-logo-202x80.svg Corcept Logo https://www.korlym.com/hcp/dosing/initiating-korlym 2026-04-30 https://www.korlym.com/images/hcp/site-nav-korlym-logo.svg Korlym® (mifepristone) 300 mg tablets logo. https://www.korlym.com/images/footer-corcept-logo-202x80.svg Corcept Logo https://www.korlym.com/hcp/dosing/titrating-korlym 2026-04-30 https://www.korlym.com/images/hcp/site-nav-korlym-logo.svg Korlym® (mifepristone) 300 mg tablets logo. https://www.korlym.com/images/footer-corcept-logo-202x80.svg Corcept Logo https://www.korlym.com/hcp/access-support/corcept-cares 2026-04-30 https://www.korlym.com/images/hcp/site-nav-korlym-logo.svg Korlym® (mifepristone) 300 mg tablets logo. https://www.korlym.com/images/hcp/icons/90percent.svg Greater than ninety percent. https://www.korlym.com/images/hcp/icons/85percent.svg Greater than eighty-five percent. https://www.korlym.com/images/hcp/_optimized/corcept-cares_desktop-opt-1080.WEBP Corcept Cares patient advocate. https://www.korlym.com/images/footer-corcept-logo-202x80.svg Corcept Logo https://www.korlym.com/hcp/contact-a-rep 2026-05-01 https://www.korlym.com/images/hcp/site-nav-korlym-logo.svg Korlym® (mifepristone) 300 mg tablets logo. https://www.korlym.com/images/footer-corcept-logo-202x80.svg Corcept Logo